1.1Carboxyl group at R1
The carboxyl carbon bonds directly to the scaffold at R1. The two oxygen atoms provide hydrogen-bonding sites and share the negative charge when the group is deprotonated.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The carboxyl carbon bonds directly to the scaffold at R1. The two oxygen atoms provide hydrogen-bonding sites and share the negative charge when the group is deprotonated.
A 5-cyanopyridin-2-yl group bonds to the scaffold through pyridine C2 and carries cyano at C5. The two attachment sites lie across the planar ring from one another, and the pyridine nitrogen provides a hydrogen-bond acceptor.
A 6-cyanonaphthalen-2-yl group bonds to the scaffold at C2 and carries cyano at C6. The fused carbon rings hold the two attachments in a rigid aromatic plane.
A pyridine carbon bonds directly to cyclohexane C1, and a cyano group bonds to cyclohexane C4. The trans configuration allows both substituents to occupy equatorial positions in the same chair conformation.
A 4-cyanooxan-4-yl group bonds to the scaffold through C4, which also bears cyano. The ring adopts a chair conformation, and the oxygen opposite C4 provides a hydrogen-bond acceptor.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical training kit uses thiopyranopyrimidinone derivatives bearing cyano, fluoro, or trifluoromethyl groups on the same phenyl attachment. Individual stock solutions establish retention times and mass signals by liquid chromatography coupled to mass spectrometry. A mixed sample lets trainees assign peaks by matching both measurements to the individual references.
A sulfone replaces the thioether in the six-membered sulfur-containing ring of the fused pyrimidinone scaffold. The ring sulfur retains both carbon bonds and carries two oxygen atoms. Oxidation with excess meta-chloroperbenzoic acid converts the isolated thioether to the sulfone, and liquid chromatography coupled to mass spectrometry tracks the sulfoxide intermediate and sulfone product.
A two-carbon ethylene linker replaces the vinyl linker between C2 of the thiopyranopyrimidinone core and the terminal aryl ring. For a cyano-substituted phenyl derivative, the corresponding 3-(cyanophenyl)propanimidamide supplies the saturated side chain during condensation with a cyclic beta-keto ester that supplies the sulfur-containing ring. Proton nuclear magnetic resonance identifies the two linker methylene groups in the isolated product.
A screening panel contains 12 derivatives with a common thiopyranopyrimidinone core and a phenyl group attached at C2. Each phenyl ring carries one of four substituents, fluoro, chloro, cyano, or trifluoromethyl, at the 2-, 3-, or 4-position relative to its attachment to the core. The plate holds each derivative in duplicate at 1, 3, 10, and 30 micromolar, with a matched solvent concentration across wells.
A porous wound-contact layer supports a crosslinked hydrogel reservoir containing a dispersed thiopyranopyrimidinone derivative, and a backing film covers the outer face. Water entering from the contact side hydrates the gel and dissolves part of the compound. The dissolved fraction diffuses through the contact layer, and a diffusion cell with a buffered receiver measures cumulative release by liquid chromatography.
An automated microscope images confluent keratinocyte cultures after a uniform gap is introduced in each well and a liquid handler dispenses thiopyranopyrimidinone derivatives. Image analysis software segments the cell-free area and expresses its change as a fraction of the starting area. The software reports time courses by dose alongside vehicle controls and pairs each course with an endpoint viability measurement.
A single deuterium atom occupies R1a. The bond at that position has a lower stretching frequency than the corresponding bond to protium.
The scaffold bonds to C1 of a phenyl ring, and phenyl C4 bonds directly to C2 of a pyridine ring. Pyridine C5 carries cyano as R3, and phenyl C2 carries fluorine as R3a.
Thiophene C2 bonds to the scaffold, and thiophene C5 bonds directly to pyridine C2. Pyridine C5 carries cyano as R3, and thiophene C3 carries methyl as R3a.
Cyclohexane C1 bonds to the scaffold, and C4 bears a 4-chlorophenyl group with chlorine as R3. The two cyclohexane substituents have a trans relationship and occupy equatorial positions in the same chair conformation.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
R1 is selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, azido, nitroso, oxo (═O), thioxo (═S), —SO2—, amino, hydrazino, formyl, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, C7-12 arylalkoxy, C3-8 cycloalkyl, C3-8 cycloalkyloxy, C5-6 aryl, C2-10 heterocyclyl, C1-6 heteroaryl, alkylamino, —COORa, —C(O)Rb, —C(S)Ra, —C(O)NRaRb, —C(S)NRaRb, —NRaC(O)NRbRc, NRaC(S)NRbRc, —N(Ra)SORb, —N(Ra)SO2Rb, —NRaC(O)ORb, —NRaRb, —NRaC(O)Rb—, —NRaC(S)Rb—B · US 11,352,322 B2 · ¶ 14
A substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine compound of formula I, wherein R1 denotes a branched or unbranched C1–C5-alkyl, a halogen other than chlorine at the 4-position, a branched or unbranched O—C1–C5-alkyl, a branched or unbranched S—C1–C5-alkyl, or a salt thereof of a physiologically compatible acid.A · US 7,034,041 B2 · claim 1
R2 is selected from the group consisting of —OR7, aniline, amino C5-6 aryl, and amino C1-6 heteroaryl, wherein aniline, amino C5-6 aryl, and amino C1-6 heteroaryl, is optionally substituted with one or more of the groups selected from C1-8 alkyl, halogen, OH, amino, and cyano;B · US 11,352,322 B2 · ¶ 14
Y is a bond or is selected from the group consisting of substituted or unsubstituted C1-8 alkyl, C1-8 alkenyl, C1-8 alkynyl, C5-6 aryl, C1-6 heteroaryl, C2-10 heterocyclyl, C3-8 cycloalkyl, —CO—, and —CO—C2-10 heterocyclyl; wherein C1-8 alkyl, C5-6 aryl, C1-6 heteroaryl, C2-10 heterocyclyl, C3-8 cycloalkyl, is optionally substituted with one or more of the groups selected from hydrogen, C1-6 alkyl, oxo (═O), C3-8 cycloalkyl, halogen, OH, and cyano;B · US 11,352,322 B2 · ¶ 14
Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine (compounds), methods for the production thereof, pharmaceutical compositions containing said compounds, and methods of treatment of pain and other diseases using the pharmaceutical compositions.A · US 7,034,041 B2 · abstract
According to an embodiment, the present disclosure relates to a compound of Formula I or its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof, which is selected from a group consisting of: 1) (E)3(4(((2(4-Cyclopropylphenyl)cyclopropyl)amino)methyl)phenyl)-N-hydroxyacrylamide TFA salt 2) (E)-3-(4-{[2-(4-Fluoro-phenyl)-cyclopropylamino]-B · US 11,352,322 B2 · ¶ 183
An empty cell means only that no passage was reproduced there.
Pain is one of the main symptoms in clinical practice, and there is a worldwide demand for effective pain treatment.A · US 7,034,041 B2 · ¶ 3
The invention relates to substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridines, a process for their production, medicaments containing these compounds, the use of these substances for the production of medicaments as well as method for treating pain using the medicaments.A · US 7,034,041 B2 · ¶ 2
The compounds described herein are dual inhibitors of lysine specific demethylase (LSD) and histone deacetylase (HDAC) and also arrest cell growth in neoplastic cells, thereby inhibiting proliferation.B · US 11,352,322 B2 · ¶ 3
These compounds can be used as prophylactic or therapeutic agents for treating cancer, schizophrenia, Alzheimer's disease, Parkinson's disease, and the like.B · US 11,352,322 B2 · ¶ 3
patent.fyi, US 2026/0356860 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356860/, SHA-256 ff1fe632e4fda393df2db486339368c5a87cf087a2f94f87294cb77626b2073d